BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Y, Yang W, Smith CA, Cheng C, Karol SE, Larsen EC, Winick N, Carroll WL, Loh ML, Raetz EA, Hunger SP, Winter SS, Dunsmore KP, Devidas M, Yang JJ, Evans WE, Jeha S, Pui C, Inaba H, Relling MV. Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clin Pharmacol Ther 2021;110:794-802. [DOI: 10.1002/cpt.2241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Van Driest SL, Cascorbi I. Progress and Challenges in Pharmacogenomics. Clin Pharmacol Ther 2021;110:529-32. [PMID: 34412159 DOI: 10.1002/cpt.2359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kondyli M, Tremblay DÉ, Rezgui A, Serfaty SA, Gagné V, Ribère M, Laverdière C, Leclerc JM, Tran TH, Sinnett D, Krajinovic M. Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols. Leuk Res 2021;109:106650. [PMID: 34198115 DOI: 10.1016/j.leukres.2021.106650] [Reference Citation Analysis]
3 Liu S, Gao C, Wu Y, Lin W, Li J, Xue T, Wang L, Zheng H, Zhang R. HLA-DRB1*16:02 is associated with PEG-asparaginase hypersensitivity. Pharmacogenomics 2021;22:1135-42. [PMID: 34747637 DOI: 10.2217/pgs-2021-0107] [Reference Citation Analysis]